March 15, 2019
The Ministry of Health, Labor and Welfare (MHLW) on March 13 designated Takeda Pharmaceutical’s allogeneic stem cell therapy Cx601 (darvadstrocel) as an orphan regenerative medicine product in Japan. Cx601, the first cell therapy for Takeda, is expected to be indicated...read more